The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Subgroup analysis of MagnetisMM-3: less frequent dosing of elranatamab for multiple myeloma
Ajay Nooka, MD, MPH, FACP, Emory University Winship Cancer Institute, Atlanta, GA, comments on a subgroup analysis of MagnetisMM-3 (NCT04649359), investigating less frequent dosing of elranatamab for the treatment of multiple myeloma. Dr Nooka notes that a response-adapted dosing strategy can be used, without compromising efficacy or increasing adverse events. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the studies were designed in such a way that the bispecific antibodies are given every week. So for patients that are getting a response, if the patients are continuing these drugs beyond the six-month mark, there is an opportunity for us to go to every other week dosing and every four-week dosing eventually. So it is all response-adapted change in the schedule for the specific patients. So what was very interesting was when patients achieve a response initially, and when you change the frequency of the dosing to farther dosing with increasing the dosing intervals, you see the maintenance of the efficacy at the same time, the reduction in the adverse event profile...
So the studies were designed in such a way that the bispecific antibodies are given every week. So for patients that are getting a response, if the patients are continuing these drugs beyond the six-month mark, there is an opportunity for us to go to every other week dosing and every four-week dosing eventually. So it is all response-adapted change in the schedule for the specific patients. So what was very interesting was when patients achieve a response initially, and when you change the frequency of the dosing to farther dosing with increasing the dosing intervals, you see the maintenance of the efficacy at the same time, the reduction in the adverse event profile. So the safety is improved, the efficacy is preserved, which makes us start to wonder, could we move the segment of where we’re talking about those patients that are getting less frequent dosing to earlier in the course when the patients get a response earlier? So this is very interesting data, which is also thought-provoking to say that patients do not need to be bombarded with this Q-weekly dosing, and likely we have an opportunity to do less frequent dosing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
